Video

Dr. Pishvaian on FDA Approval of Atezolizumab Plus Bevacizumab in HCC

Michael J. Pishvaian, MD, PhD, discusses the FDA approval of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of patients with hepatocellular carcinoma (HCC).

Michael J. Pishvaian, MD, PhD, a gastrointestinal oncologist and head of the Phase I Program at the Georgetown Lombardi Comprehensive Cancer Center, discusses the FDA approval of the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for the treatment of patients with hepatocellular carcinoma (HCC).

The combination of the PD-L1 inhibitor and anti-VEGF agent was approved by the FDA on May 29, 2020 for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy. The approval is based on findings from the phase 3 IMbrave150 study, which demonstrated that atezolizumab plus bevacizumab led to a 42% reduction in the risk of death compared with sorafenib (Nexavar; HR, 0.58; 95% CI, 0.42-0.79; P = .0006). The combination was also associated with a 41% reduction in the risk of disease progression or death versus sorafenib (HR, 0.59; 95% CI, 0.47-0.76; P <.0001).

This combination has been shown to improve outcomes for patients with advanced HCC, demonstrating very durable responses, Pishvaian says. Some patients are achieving complete responses, allowing them to return to a normal quality of life.

Multikinase inhibitors were the traditional therapies used in this space, but although these drugs were effective, they came with notable toxicities. While immunotherapy agents bring along their own unique set of adverse events, this combination has been generally well tolerated in the vast majority of patients.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD